GLP-1RAs in the cardiovascular system In the cardiovascular system, GLP-1 can reduce cardiac ischemia-reperfusion injury through the activation of specific signaling pathways, such as the PI3K/Akt pathway
PlexusDx patients should consult their prescribing clinician before adding any supplements or medications to ensure compatibility with their personalized treatment protocol
This product is supplied strictly for laboratory research purposes only and is not intended for human consumption, clinical use or veterinary use
On the other hand, a single dose of 600mg reduces the need for multiple doses
Potential side effects include injection site reactions (redness, swelling, pain), mild nausea (rare), headache (uncommon), fatigue (rare)